Table 1.
Unresected group | Resected group | ||||
No | % | No | % | p Value | |
Total | 82 | 100 | 280 | 100 | |
Median time from diagnosis to chemotherapy (days) | 26 | 52 | |||
Sex | |||||
Male | 60 | 73 | 169 | 60 | |
Female | 22 | 27 | 111 | 40 | 0.03 |
Age (y) | |||||
Median (range) | 59 (19–80) | 62 (30–82) | |||
PS at commencement of chemotherapy | |||||
0–1 | 51 | 62 | 225 | 80 | |
⩾2 | 31 | 38 | 55 | 20 | 0.001 |
Site of primary tumour | |||||
Right sided | 13 | 16 | 69 | 25 | |
Residual colon | 31 | 38 | 119 | 43 | |
Rectum | 38 | 46 | 92 | 33 | 0.06 |
Sites of metastases | |||||
Peritoneal/omental | 11 | 13 | 56 | 20 | |
Non-peritoneal/omental | 71 | 87 | 224 | 80 | 0.18 |
Biochemical parameters | |||||
Mean serum alk phosph (U/l) | 329 | 179 | <0.001 | ||
Mean serum albumin (g/l) | 34.5 | 38.7 | <0.001 | ||
Mean CEA (μg/l) | 3139 | 809 | 0.006 |
PS, performance status; CEA, carcinoembryonic antigen; Alk phosph, alkaline phosphatase.